JP2016538248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538248A5 JP2016538248A5 JP2016521604A JP2016521604A JP2016538248A5 JP 2016538248 A5 JP2016538248 A5 JP 2016538248A5 JP 2016521604 A JP2016521604 A JP 2016521604A JP 2016521604 A JP2016521604 A JP 2016521604A JP 2016538248 A5 JP2016538248 A5 JP 2016538248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 14
- 108010028554 LDL Cholesterol Proteins 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims 5
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 230000008816 organ damage Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 206010067484 Adverse reaction Diseases 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 2
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 2
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000006838 adverse reaction Effects 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 102000053786 human PCSK9 Human genes 0.000 claims 2
- 231100000518 lethal Toxicity 0.000 claims 2
- 230000001665 lethal effect Effects 0.000 claims 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- 206010050403 Carotid artery dissection Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims 1
- 206010038378 Renal artery stenosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 229940049950 atorvastatin 10 mg Drugs 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 210000001715 carotid artery Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- -1 fibrate Chemical compound 0.000 claims 1
- 229940050513 fluvastatin 40 mg Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 229940080794 lovastatin 20 mg Drugs 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 210000002254 renal artery Anatomy 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 229940103117 simvastatin 10 mg Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890154P | 2013-10-11 | 2013-10-11 | |
| US61/890,154 | 2013-10-11 | ||
| US201461923103P | 2014-01-02 | 2014-01-02 | |
| US61/923,103 | 2014-01-02 | ||
| US201461955514P | 2014-03-19 | 2014-03-19 | |
| US61/955,514 | 2014-03-19 | ||
| US201462004620P | 2014-05-29 | 2014-05-29 | |
| US62/004,620 | 2014-05-29 | ||
| US201462025104P | 2014-07-16 | 2014-07-16 | |
| US62/025,104 | 2014-07-16 | ||
| EP14306221.4 | 2014-07-31 | ||
| EP14306221 | 2014-07-31 | ||
| US201462054571P | 2014-09-24 | 2014-09-24 | |
| US62/054,571 | 2014-09-24 | ||
| EP14306584.5 | 2014-10-09 | ||
| EP14306584 | 2014-10-09 | ||
| PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146940A Division JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538248A JP2016538248A (ja) | 2016-12-08 |
| JP2016538248A5 true JP2016538248A5 (enExample) | 2017-11-16 |
| JP6846931B2 JP6846931B2 (ja) | 2021-03-24 |
Family
ID=52813751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521604A Active JP6846931B2 (ja) | 2013-10-11 | 2014-10-10 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
| JP2019146940A Active JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019146940A Active JP6994484B2 (ja) | 2013-10-11 | 2019-08-09 | 高脂血症を処置するためのｐｃｓｋ９阻害剤の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150140002A1 (enExample) |
| EP (2) | EP3689913B1 (enExample) |
| JP (2) | JP6846931B2 (enExample) |
| KR (3) | KR20160062166A (enExample) |
| CN (3) | CN115154599A (enExample) |
| AU (2) | AU2014331754B2 (enExample) |
| CA (1) | CA2926942A1 (enExample) |
| EA (1) | EA037526B1 (enExample) |
| ES (1) | ES2914978T3 (enExample) |
| IL (1) | IL244995B (enExample) |
| MX (3) | MX373298B (enExample) |
| PL (2) | PL3055333T4 (enExample) |
| TW (1) | TWI669131B (enExample) |
| WO (1) | WO2015054619A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PL4252857T3 (pl) | 2011-09-16 | 2025-03-03 | Regeneron Pharmaceuticals, Inc. | Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CA2914721A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 |
| JP6616298B2 (ja) | 2013-11-12 | 2019-12-04 | サノフィ・バイオテクノロジー | Ｐｃｓｋ９阻害剤と共に使用するための投薬レジメン |
| WO2016010927A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| CN107635512A (zh) * | 2015-04-15 | 2018-01-26 | 康斯瓦维有限责任公司 | 用于抑制天然心脏瓣膜、被支撑的心脏瓣膜或生物假体的狭窄、阻塞或钙化的装置和方法 |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-ｐｃｓｋ９ 항체 |
| CA3058567A1 (en) | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| US20200131576A1 (en) | 2017-04-25 | 2020-04-30 | The Brigham And Women's Hospital, Inc. | IL-8, IL-6, IL-1 Beta and TET2 and DNMT3A in Atherosclerosis |
| CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
| CN109963877B (zh) * | 2017-06-14 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| AU2019231703A1 (en) * | 2018-03-06 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Use of PCSK9 inhibitor for reducing cardiovascular risk |
| JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
| CR20210441A (es) | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Inhibidores de la pcsk9 y métodos de uso de los mismos |
| AU2020388182A1 (en) * | 2019-11-18 | 2022-06-02 | Ad Pharmaceuticals Co., Ltd. | Anti-PCSK9 antibody and use thereof |
| EP4072672A1 (en) * | 2019-12-10 | 2022-10-19 | Regeneron Pharmaceuticals, Inc. | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
| CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| MX347602B (es) * | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| PL4252857T3 (pl) * | 2011-09-16 | 2025-03-03 | Regeneron Pharmaceuticals, Inc. | Sposoby redukowania poziomów lipoproteiny(a) poprzez podawanie inhibitora proproteinowej konwertazy subtylizyny keksyny-9 (pcsk9) |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en not_active Ceased
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active Ceased
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Ceased
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 MX MX2016004580A patent/MX373298B/es active IP Right Grant
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Ceased
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538248A5 (enExample) | ||
| JP2017528427A5 (enExample) | ||
| JP2017506626A5 (enExample) | ||
| JP2022177142A5 (enExample) | ||
| US20230406957A1 (en) | Dosing regimens for use with pcsk9 inhibitors | |
| JP2016538277A5 (enExample) | ||
| JP2024147744A (ja) | 心血管リスクを低減させる方法 | |
| JP2016520616A5 (enExample) | ||
| JP2019514907A5 (enExample) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2017522316A5 (enExample) | ||
| JP2016522211A5 (enExample) | ||
| HRP20200545T1 (hr) | Postupci liječenja ili sprječavanja poremećaja povezanih sa kolesterolom | |
| Di Ciaula et al. | Therapeutic reflections in cholesterol homeostasis and gallstone disease: a review | |
| JP2016523847A5 (enExample) | ||
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2015503590A5 (enExample) | ||
| RU2013139727A (ru) | Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов | |
| RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| RU2017104799A (ru) | Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию | |
| JP2022078306A (ja) | Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法 | |
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| JP2019512472A5 (enExample) | ||
| Toth et al. | Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction | |
| Taher et al. | An update on dyslipidemia management and medications: a review |